Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
HCC
Interventions
DRUG

PD-1 monoclonal antibody and lenvatinib

Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.

DRUG

PD-1 monoclonal antibody

Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.

Trial Locations (1)

430000

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan

All Listed Sponsors
lead

Chen Xiaoping

OTHER